Member Info for Alwaysone

@DonBroco - thansk for this and yes I did see all that about the delay and the potential newco on Aim.
It's still Gabriel's desire to move the Nas though, I have it on email from them as well from 2 weeks back.

Punit, what is it you read here day? I have a full time job and just dip in and out and still keep up to date.
Last time I am posting as you can be a tad irritatting, sorry
2 Wall Street analysts have issued ratings and price targets for Tiziana Life Sciences in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 251.56%. The high price target for TLSA is $25.00 and the low price target for TLSA is $20.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

https://www.marketbeat.com/stocks/NASDAQ/TLSA/price-target/
5/29/2020 HC Wainwright Reiterated Rating Buy $25.00 Low
9/10/2019 Laidlaw Set Price Target Buy $20.00 N/A

Highly regarded Wall Street healthcare analyst Raghuram Selvaraju rates Tiziana Life Sciences PLC a ‘buy’ with US$25/£5 price target
https://www.proactiveinvestors.co.uk/companies/news/920721/highly-regarded-wall-street-healthcare-analyst-raghuram-selvaraju-rates-tiziana-life-sciences-plc-a-buy-with-us255-price-target-920721.html

The boss is aiming at some point to move to NASDAQ as they provide better valuations to Pharma stocks ( Gabriel's own words)
No idea why you'd think AIM is day traders as the spread puts them off, it did me for a couple of weeks and I eventually bought in at a higher price as I thought the company had a compelling line up/future.
You can see it's a longer term hold for big rewards, as it refuses to budge up to the next level at the moment, even with good news....but when it does, it will be a sharp move up I'm sure.
Or a company takeover bid at a premium, that will move it up very fast lol

Just like GDR....80p placing when it was racing above £2.40. At least this is £1.20 and the market seemed aware of it yesterday. GDR did it straight after two RNS in 3 days and collapsed. Doesn't seem so bad here IMHO and still a great investment imho

Yes, VERY frustrating, I think the ATMs.
That said, I think this is why Gabriele prefers to be on Nas not Aim as they value pharma shares higher

KEY point fo us
· Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.

The rationale of this decision is that, as a standalone genomics-based personalized medicine company and separate legal entity, StemPrintER could:

· Secure separate financial resources, with the goal of enabling accelerated development of the StemPrintER genomic test;

· Separate StemPrintER from Tiziana's biotechnology and pharmaceutical businesses so it may focus on the personalized medicine market; and



· Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.



The Board is taking the necessary preliminary steps in preparation for a potential spin-out, including the incorporation of a new subsidiary to hold the relevant assets. The Company will also put proposals to shareholders at the Annual General Meeting to obtain the approval necessary for a capital reduction which will be required to implement the demerger.

Notwithstanding that the required approval for the capital reduction will be sought, these considerations remain at an early stage and there can be no guarantee that the demerger will be completed. The approval of the capital reduction will enable the Board, in due course, to declare distribution in specie of shares in the new StemPrintER entity to existing Tiziana shareholders.

No record date has yet been set for the entitlement to shares in the new StemPrintER entity as a number of technical, legal and accounting processes need to be completed before the demerger can be formally put to shareholders of Tiziana for approval. For the avoidance of doubt StemPrintER will remain a group business until such time as shareholders formally approve proposals for a demerger.

Do you mean the ATM sales here? I think it's mainly these that are keeping the lid on the share rise......
Plus yes, Gabriele plus directors can pretty much do what they like with their control of the company, although I'm not sure what % vote they require on an GM vote?

I have stated before and retain my opinion that there is a deal already in the wings for Stem. yesterday’s release of money is IMHO to expedite this process and we will see announcement of record date and decision on this much sooner than most expect. (“Aggressively pursuing”)

I also wonder if the vote will be passed on demerger without a public vote as the board and key investors own enough of this company to make that decision without us. (I also wonder if some of the recent larger delayed buys may also be the board and key investors strengthening that position)

I nearly top sliced to get into PHE yesterday at 2.5p, wish I had now, as we seem to be flat for a bit at the moment, even with all the good news.....frustrating to say the least

Agreed. The US market will love this!
Watch later on

As an experienced Investor in U.S. Biotech I'm confident that the U.S. Investor community who are aware of #tils will like this - especially the move into Phase 2 eg. a move from dose finding and safety in healthy humans to a full trial in patients

Yes, so what

Forward selling occurs when a company agrees to issue shares to a third party and that third party sells those shares in the market, prior to actually receiving them.

But they need to convert the warrants first
It’s the ATM imho

RE: Trades03 Jun 2020 09:30
How can they be clearing stock that hasnt even been sold or issued yet. The ATM facilities is used IF and when needed.

New overhang is the warrant holders selling. aimho

AVCT Mcap 284m and 209m shares in issue
TILS Mcap 167m and 161m shares in issue

How the f@#k can avct have a higher mcap than tills?
Admittedly avct a fine prospect but tils a humongous monster in the making and in my opinion BIGGER

100% yes. But DYOR.
Only time before this multibags

Unless the ATM sales again to raise more cash
SCREAMING buy this stock

New York/London, 4 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the Chairman of the Company's Scientific Advisory Board, Dr. Howard Weiner, has received a competitive research grant from the National Institutes of Health (NIH) to investigate nasal anti-CD3 for the treatment of Alzheimer's disease.



The demonstration that nasally administered anti-CD3 ******s disease processes underlying the progression of Alzheimer's disease in animal models, further expands clinical development of nasally administered Foralumab, the only entirely human anti-CD3 monoclonal antibody, for the potential treatment of Alzheimer's and other neurodegerative diseases in humans.



The Company has a worldwide exclusive license for nasal administration of anti-CD3 mAbs for treatment of neurodegenerative diseases, including Alzheimer's disease, from Brigham and Women's Hospital, Harvard Medical School, Boston. To date the Company has successfully completed two phase 1 trials and intends to initiate two phase 2 trials with nasally and orally administered Foralumab shortly for treatment of progressive multiple sclerosis (pro-MS) and Crohn's disease, respectively.

"Nasal administration of Foralumab is a potentially revolutionary approach to treat patients with Alzheimer's disease. Preclinical animal studies have established that nasal administration of anti-CD3 can modulate brain microglia and ameliorate disease in animal models. This is a major scientific advancement that provides the basis to move forward with clinical development of nasally administered Foralumab in Alzheimer's disease," commented Dr. Weiner, who is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Ann Romney Center for Neurologic Diseases at the Brigham & Women's Hospital. "Targeting microglia with nasal anti-CD3 is a first-in-class immunotherapeutic approach to treat Alzheimer's disease."

Alzheimer's disease is the most common cause of dementia, which affects millions of people worldwide. It is now recognized that brain microglia have a critical role in Alzheimer's disease. In an unexpected discovery, Dr. Weiner found that nasal anti-CD3 modulates brain microglia in animal models. Treatment with anti-CD3 is known to stimulate T regulatory (Tregs) cells, which have the ability to cross the blood-brain barrier (1) The effect of nasal anti-CD3 in dampening microglial activation led Dr. Weiner's team at the Ann Romney Center for Neurologic Diseases at Brigham and Women's Medical Center to evaluate nasally administered Foralumab for pro-MS (2). In 2019, Dr. Weiner successfully completed a Phase 1 study with nasally administered Foralumab in healthy volunteers in a dose-ranging trial. A subsequent Phase 2 trial in patients with pro-MS will be

https://www.google.com/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/921111

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said the chairman of its scientific advisory board has received a research grant from the National Institutes of Health in the US to investigate the company’s nasal anti-CD3 drug, Foralumab, for the treatment of Alzheimer’s disease.

The NIH award provides third-party validation of the work of Dr Howard Weiner in an area of great unmet medical need.

He believes the nasal administration of Foralumab is a “potentially revolutionary approach” to treat patients with Alzheimer’s.

To date the company has successfully completed two phase I studies on the drug candidate, administered both nasally and orally for the treatment of progressive multiple sclerosis and Crohn’s disease.

It will be hoped this early work will speed up the clinical progress in Alzheimer’s
Etc

Yes agree, £1.60 and a much much stronger place. Huge buy and hold

But what happens if one of the big boys bids for the company with big bucks before a potential split? No good if you don’t own the shares then eh.

I’m not totally convinced, as I’ve said before that this split is a canny way of getting more profile on StemprintER.

I do agree with Silverback here.
All blue sky I know but also very sound I’m sure. Does seem too good to be true I know. Share price will rerate soon I’m sure.
The covid connection isn’t really helping this week BUT it is that that led many of us to find this company.

I agree with you totally here. 3 days of rises in the Footsie have taken the shine off, hence I’m quietly confident of a good ending to the week and get to £1.10 min maybe £1.15. Let’s see